NTRK1 and neoplasm: Sorafenib (BAY 43-9006) is a multikinase inhibitor with anti-tumor activity in various tumor models [21], which can inhibit the Raf/MEK/ERK signaling pathway [22], and inhibit receptor tyrosine kinases which promote angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)1, VEGFR2, VEGFR 3, platelet-derived growth factor receptor -β(PDGFR-β), Flt3 and c-Kit, playing a key role in tumor cell proliferation and tumor angiogenesis [23–25].